Search Results
Your search for ,FeW matches 3003 pages
Showing 151 - 200PERSEUS: Daratumumab Regimen Significantly Improves Progression-Free Survival in Newly Diagnosed Multiple Myeloma
The addition of the CD38 monoclonal antibody daratumumab to a standard regimen for patients with newly diagnosed transplant-eligible multiple myeloma significantly prolonged progression-free survival vs standard treatment in the phase III PERSEUS trial. The study was reported as a late-breaking...
AUGMENT-101 Trial: Menin Inhibitor Revumenib Shows Activity in KMT2A-Rearranged Acute Leukemia
In heavily pretreated patients with a challenging type of acute leukemia, the menin inhibitor revumenib demonstrated clinically meaningful activity, including high rates of response and measurable residual disease (MRD) negativity, according to the efficacy and safety results of the phase II...
American Cancer Society Annual Report Shows Cancer Mortality Still Declining, but Cancer Incidence Is Projected to Top 2 Million
Although overall cancer mortality has continued to decline, resulting in over 4 million fewer deaths in the United States since 1991, increasing incidence for 6 of the top 10 cancers pushed the projected number of new diagnoses to over 2 million (2,001,140) for the first time, according to the...
Young Women With Breast Cancer: Discussing vs Pursuing Fertility Preservation
In 2023, nearly 300,000 new cases of invasive breast cancer were diagnosed in the United States, and approximately 56,000 new cases of ductal carcinoma in situ were diagnosed. Although most of those cancers are diagnosed in older adults, about 9% of all new cases of breast cancer are found in women ...
Novel Risk Model May Personalize Prognosis Prediction in Patients With Multiple Myeloma
Researchers have developed a novel computational model for personalized prognosis prediction in patients with newly diagnosed multiple myeloma, according to a new study published by Maura et al in the Journal of Clinical Oncology. Their model for individualized risk in multiple myeloma, or IRMMa,...
Some Patients With Breast Cancer May Safely Avoid Locoregional Irradiation After Neoadjuvant Chemotherapy
It may be possible for some patients with breast cancer to avoid adjuvant regional nodal irradiation safely, according to the results of the NRG Oncology/NSABP B-51/RTOG 1304 clinical trial presented at the 2023 San Antonio Breast Cancer Symposium.1 These findings particularly apply to patients...
Rare T Cells May Help Predict Immunotherapy Response in Patients With Skin Cancer
A rare subset of T cells called V-delta 1 gamma-delta (Vd1-gd) T cells could help predict which patients with advanced skin cancer may be responsive to immunotherapy, according to a novel study published by Davies et al in Nature Cancer. The new findings may lead to the development of new and more...
Expert Point of View: Elizabeth Smyth, MD
Invited discussant of the phase I trial of the claudin 18.2-specific antibody-drug conjugate CMG901 in advanced gastric or gastroesophageal junction cancer was Elizabeth Smyth, MD, of Oxford University Hospitals NHS Foundation Trust. She said CMG901 demonstrated “encouraging results,” but more...
I Don’t Want Cancer to Define Me
Except for a series of unexplained multiple broken bones and inexplicable excruciating pain in my right hip and leg, I had no other hallmarks of multiple myeloma when I was diagnosed with the disease at age 48 in 2014. My blood test values were all normal, and I didn’t have anemia or kidney damage. ...
New Findings Challenge Widely Accepted Beliefs About the Relative Efficacy of Opioids in Treating Cancer Pain
Investigators have uncovered concerningly large gaps in evidence regarding the true benefits of opioids for pain relief in patients with cancer, according to a novel study published by Shaheed et al in CA: A Cancer Journal for Clinicians. The new findings could challenge the commonly held view that ...
All Adult Oncologists Are Geriatric Oncologists
The data developed over the past few years have overwhelmingly favored geriatric assessment as part of the routine care for older patients with cancer. It has become the standard of care. ASCO has recently published a Practical Geriatric Assessment to aid in the implementation of this vital...
Cardiovascular Health of Women Treated for Cancer: Understanding the Long-Term Risks
At the 2023 Global Cardio-Oncology Summit in Madrid, in a joint session with ASCO and the International Cardio-Oncology Society, Anita Arnold, DO, FACC, MBA, Director, Noninvasive Cardiology, and Director of Cardio-Oncology, Lee Memorial Health Systems, Fort Myers, Florida, discussed the...
HER2CLIMB-02: Tucatinib Plus T-DM1 Extends Progression-Free Survival vs T-DM1 Alone in Advanced HER2-Positive Breast Cancer
Adding the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) to the HER2-targeted agent tucatinib extended progression-free survival by about 2 months vs treatment with T-DM1 alone among patients with unresectable, locally advanced or metastatic HER2-positive breast cancer, according to...
ConcertAI to Acquire CancerLinQ
On December 11, ConcertAI announced the acquisition of CancerLinQ, previously a subsidiary of ASCO. In conjunction with the acquisition, ASCO will maintain a multiyear cooperation agreement with CancerLinQ. Building on CancerLinQ’s mission when launched by ASCO in 2013, this new venture will...
Ruxolitinib Plus Navitoclax May Reduce Spleen Volume in Patients With Myelofibrosis
The Janus kinase (JAK) inhibitor ruxolitinib plus the B-cell lymphoma 2 protein inhibitor navitoclax may be twice as effective at spleen volume reduction compared with standard-of-care ruxolitinib monotherapy in adult patients with intermediate- or high-risk myelofibrosis, according to new findings ...
Novel BET Inhibitor for Advanced Myelofibrosis
Researchers may have uncovered a new type of targeted therapy for patients with advanced myelofibrosis, according to new findings presented by Watts et al at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 750). Background Historically, there have been few...
CAR T-Cell Therapy Safe, Feasible for Patients With Lymphoma in Complete Remission Before Cell Therapy Begins
Data presented at the 2023 ASH Annual Meeting & Exposition suggest that chimeric antigen receptor (CAR) T-cell immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins (Abstract 615). While the findings do not answer the...
Supportive Parents and Early Love of Science Lead to a Career in Hematology Oncology for Nina Shah, MD
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Nina Shah, MD, Global Head of Multiple Myeloma Clinical Development and Strategy, Hematology, Oncology Research and Development at AstraZeneca. She is a hematologist who specializes in...
Potentially Targetable Fusion RNAs May Be More Common in Metastatic Breast Cancer Than Previously Realized
Comprehensive profiling of fusion RNAs present in a large cohort of metastatic breast tumors revealed unique fusion mutations that may be therapeutically targetable, according to results presented at the 2023 San Antonio Breast Cancer Symposium (Abstract GS03-09). Fusion mutations occur when a...
Understanding the Treatment Options for PD-1–Refractory Melanoma
For the treatment of advanced melanoma that is refractory to anti–PD-1 antibodies, there is no standard approach. The various options, with a look to the future, were discussed by Melinda L. Yushak, MD, MPH, Assistant Professor of Hematology and Oncology at Emory University School of Medicine, at...
Tucatinib Plus T-DM1 May Benefit Patients With Advanced or Metastatic HER2-Positive Breast Cancer
A combination of two HER2-targeted drugs—tucatinib and ado-trastuzumab emtansine (T-DM1), extended progression-free survival among patients with unresectable, locally advanced, or metastatic HER2-positive breast cancer compared with T-DM1 alone, according to results from the HER2CLIMB-02 trial...
Regular Screening Mammograms May Significantly Reduce Breast Cancer Mortality, Swedish Study Shows
Patients who regularly attend screening mammograms may have a reduced risk of breast cancer mortality, according to recent findings presented by Smith et al at the Radiological Society of North America (RSNA) 2023 Scientific Assembly and Annual Meeting (Abstract R1-SSBR10-4). Background Early...
Iruplinalkib Demonstrates Improved Efficacy and Tolerance vs Crizotinib in ALK Inhibitor–Naive, Advanced ALK-Positive NSCLC
The novel ALK tyrosine kinase inhibitor iruplinalkib has demonstrated potential for a difficult-to-treat subset of patients with non–small cell lung cancer (NSCLC), according to data presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.1 A...
FLAURA2 Trial: Osimertinib Plus Chemotherapy Improves Outcomes in Advanced EGFR-Positive NSCLC
First-line treatment with osimertinib plus platinum-based chemotherapy achieved a statistically significant and clinically meaningful progression-free survival improvement compared with osimertinib alone in patients with advanced epidermal growth factor receptor (EGFR)-mutated non–small cell lung...
A Cancer Diagnosis at 19 Taught Me That It Takes Constant Vigilance to Stay Mentally Healthy
A lot of my experience with cancer is hazy to me. I was taking narcotics for pain around the clock when I was diagnosed with Ewing’s sarcoma in 2013, so there are some missing memories during those early days. I was 19 and a freshman in college when my symptoms started. I have always been active in ...
Early Breast Cancer: Effect of Radiotherapy to Regional Nodes
As reported in The Lancet by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), an individual patient meta-analysis has shown that more recent—but not older—trials of regional lymph node radiotherapy vs no radiotherapy in patients with early breast cancer showed benefits of...
Patients With Lower-Extremity Lymphedema May Face Increased Risk of Skin Cancer
The risk of developing skin cancer may be twofold for patients with lymphedema, according to a recent study published by Anand et al in Mayo Clinic Proceedings. The new findings may contribute to growing information linking lymphedema to localized changes in immunity and a predisposition for...
Advancing Clinical Research on Ovarian Cancer and Overcoming Gender Inequity in Low- and Middle-Income Countries
The management of ovarian cancer remains challenging within health-care systems worldwide. Recently, clinical and translational research on ovarian cancer has led to promising advances that have improved the survival outcomes of women diagnosed with this aggressive gynecologic cancer. These...
Screening for Lung Cancer: Much Work Remains to Be Done
Remarkable progress has been made in the treatment of lung cancer in the past 10 to 15 years; it is therefore not surprising that lung cancer mortality in the United States is declining consistently, at the rate of 2% to 4% annually in recent years. Long-term survival is possible even for patients...
Having Colorectal Cancer at 32 Changed the Trajectory of My Life
I’ve been contending with health issues since I was 12, when I was diagnosed with Crohn’s disease. As I began my early 30s, I was feeling the healthiest of my life. I was working out 5 days a week and attributed sudden weight loss and fatigue to weight training and high-intensity Zumba classes....
Understanding Patient Engagement in Virtual Mind-Body Therapies
Guest Editor’s Note: Virtual platforms have grown increasingly popular for health- and wellness-promoting activities. But given patients’ unique backgrounds, capabilities, interests, and goals, promoting engagement represents a complex challenge both in the context of care delivery as well as...
Patient-Facing AI in Cancer Care
Currently most use of artificial intelligence (AI) in cancer care has been limited to diagnostics, with the U.S. Food and Drug Administration approving nearly 700 medical devices that utilize AI and/or machine learning, the majority of which are used in the fields of radiology and pathology....
Novel Strategy May Improve Outcomes in Patients With Treatment-Resistant DLBCL
Researchers have found that a DNA repair–facilitating mechanism may be responsible for a tumor’s treatment resistance and could be treated with a combination of chemotherapies, according to a recent study published by Marullo et al in Cancer Research. The mechanism involves the shuttling of...
Personalized Care May Prevent Overscreening for Colorectal Cancer in Older Patients
Researchers have found that presenting older patients with personalized information regarding the benefits and harms of colorectal cancer screenings may reduce unnecessary screenings, according to a recent study published by Saini et al in JAMA Internal Medicine. Background Colorectal cancer...
Expanded Soy Production in Brazil May Be Linked to Increased Mortality Among Pediatric Patients With ALL
Researchers have reported that soy expansion and the subsequent increase of pesticide use in Brazil’s Cerrado and Amazon biomes may correlate with an increased risk of mortality among pediatric patients with acute lymphoblastic leukemia (ALL). The study was published by Skidmore et al in...
Sotorasib Plus Panitumumab in KRAS G12C–Mutated Advanced Colorectal Cancer: CodeBreaK 300
The phase III CodeBreaK 300 trial showed that sotorasib plus panitumumab improved progression-free survival vs standard care in patients with KRAS G12C–mutated refractory metastatic colorectal cancer. Findings were presented at the European Society for Medical Oncology (ESMO) Congress 2023 (LBA10)...
PFAS Exposure May Increase Risk of Thyroid Cancer
Researchers may have discovered a link between certain per- and polyfluoroalkyl substances (PFAS)—also referred to as "forever chemicals"—and an increased risk of thyroid cancer, according to a recent study published by van Gerwen et al in eBioMedicine. Background PFAS are a large, complex group of ...
Overcoming the Challenges of Treating Adolescents and Young Adults With Cancer Living in Rural Communities
It is widely acknowledged that patients with cancer living in rural areas of the United States face limited access to medical and oncology providers, often have to travel long distances to receive care, and experience obstacles in clinical trial participation—all of which affect quality of care and ...
Getting a Cancer Diagnosis at Age 16 Has Taught Me to Live in the Present
I have been fascinated with death since I was 3 years old. I remember going to my great-grandfather’s funeral and asking my mother where my great-grandfather was. She said he is in heaven. I asked her if I were going to heaven, too, and she said, “Yes, but not for a long time.” Today, I don’t...
Major Pathologic Response to Neoadjuvant Pembrolizumab in Advanced Melanoma Trial Exceeds 50%
In exploratory analyses of results from the SWOG S1801 trial in patients with stage III to IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant pembrolizumab. These and other results of...
Almost Half of Oncology Drugs Approved Since 1998 Have Been Precision Therapies, New Study Finds
Among the 198 new oncology drugs approved by the U.S. Food and Drug Administration (FDA) between 1998 and 2022, approximately 43% of them were precision therapies, according to a recent study published by Suehnholz et al in Cancer Discovery. Background Precision oncology therapies often require...
MRI Scans Could Predict Postradiation Urinary Side Effects in Patients With Prostate Cancer
Researchers have discovered that patients with longer prostatic urethras may have an increased risk of experiencing moderate and chronic urinary side effects after receiving radiation for prostate cancer, according to a recent study published by Lee et al in Academic Radiology. The new findings...
Expert Point of View: Michail Ignatiadis, MD, PhD and Stephen R.D. Johnston, MD, PhD
The September 2023 European Society for Medical Oncology (ESMO) Virtual Plenary presentation of the NATALEE health-related quality-of-life (QOL) findings was discussed by Michail Ignatiadis, MD, PhD, and Stephen R.D. Johnston, MD, PhD. Dr. Ignatiadis is Director of the Breast Medical Oncology...
Guideline Update Reflects Recent Surge of New Data in Systemic Therapy for Melanoma
A guideline update on systemic treatment for melanoma offers new guidance in several areas, including the selection of front-line therapy for patients with metastatic disease with and without BRAF mutations, treatment of patients with earlier-stage disease in the adjuvant setting, and emerging...
NUC-1031/Cisplatin Fails to Improve Outcomes in Advanced Biliary Tract Cancer
As a first-line treatment for advanced biliary tract cancer, an experimental formulation of gemcitabine, NUC-1031, given with cisplatin failed to improve outcomes over standard gemcitabine/cisplatin in the global phase III NuTide:121 trial.1 “NuTide:121 has not advanced the field in biliary tract...
FLAURA2 Trial: Osimertinib Plus Chemotherapy Improves Outcomes in Advanced EGFR-Positive NSCLC
First-line treatment with osimertinib plus platinum-based chemotherapy achieved a statistically significant and clinically meaningful progression-free survival improvement compared with osimertinib alone in patients with advanced epidermal growth factor receptor (EGFR)-mutated non–small cell lung...
Chemotherapy Shortages Ongoing, According to New Survey
The National Comprehensive Cancer Network® (NCCN®) has released a follow-up survey on the ongoing chemotherapy shortages, refreshing findings they originally shared in June 2023. According to their results, 72% of the cancer centers surveyed continue to experience a shortage of carboplatin, and 59% ...
A Diagnosis of Ewing Sarcoma Altered the Trajectory of My Life
In August 2014, just a few weeks after my 15th birthday, my body began sending me a lot of worrisome signals that life as I knew it would soon be over. The year before, I had developed a hematoma in my right femur, which was resolved with surgery. But now the pain I was experiencing in that leg was ...
From a Sleepy Town in Pakistan, Seema A. Khan, MD, MPH, Emerges as a Leader in Surgical Oncology
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Seema A. Khan, MD, MPH, Professor of Breast Cancer Surgery at Northwestern Medicine, Feinberg School of Medicine. Along with her surgical and academic pursuits, Dr. Khan is an active...
Sexual Activity and Vaginal Dilation Associated With Fewer Side Effects After Chemoradiation for Cervical Cancer
People who engage in sexual activity or vaginal dilation after chemoradiation for cervical cancer are at lower risk for long-term side effects, according to a new study from researchers in Austria. Findings of the EMBRACE study were presented by Kirchheiner et al at the 2023 American Society for...
